Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Current Advances in the Development of Drug and Vaccine for Tuberculosis Prevention and Treatment

Sayfa
1–11
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Henceforth, currently there are 10 new or repurposed anti-TB drugs and 15new Tb vaccines with a degree of diversity in terms of vaccine delivery platforms, ranging from whole cell vaccines toadjuvanted proteins, recombinant and vectored vaccines are developed and undergoes different phase of clinical trials.Overall, this review gives the basic idea of new drug and vaccine development approaches, and their effective role andclinical trial stuts in TB prevention and treatment

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Tuberculosis remains a deadliest public health problem worldwide due to a single infectious agent, Mycobacteriumtuberculosis.
📊
Temel Bulgular & Veri:It demands more attention to combat its global impact.
💡
Sonuç & Katkı:Henceforth, currently there are 10 new or repurposed anti-TB drugs and 15new Tb vaccines with a degree of diversity in terms of vaccine delivery platforms, ranging from whole cell vaccines toadjuvanted proteins, recombinant and vectored vaccines are developed and undergoes different phase of clinical trials.Overall, this review gives the basic idea of new drug and vaccine development approaches, and their effective role andclinical trial stuts in TB prevention and treatment
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Tuberculosis remains a deadliest public health problem worldwide due to a single infectious agent, Mycobacteriumtuberculosis. It demands more attention to combat its global impact. However, in addition to treatment with drugs,prevention attempts were done for the last many years through vaccination with Bacillus Calmette- Guerinvaccine(BCG). BCG is the only licensed and commonly used vaccine worldwide especially for protection against severe forms ofpediatric TB, but not as a powerful vaccine because of unreliable against adult pulmonary TB which accounts for mostof the disease global burden. Overall efforts to safe, efficient and greater immunogenic novel drugs and better vaccinedevelopment is must to combat, prevent and treatment of both drug-resistant and drug-sensitive MTB strains for allage groups and among people with HIV. Henceforth, currently there are 10 new or repurposed anti-TB drugs and 15new Tb vaccines with a degree of diversity in terms of vaccine delivery platforms, ranging from whole cell vaccines toadjuvanted proteins, recombinant and vectored vaccines are developed and undergoes different phase of clinical trials.Overall, this review gives the basic idea of new drug and vaccine development approaches, and their effective role andclinical trial stuts in TB prevention and treatment

🔖

Bu Makaleye Atıf Yap

ESKEZİAW, B. M., GELAW, T. A., WONDİE, G. S., WORKU, M. D. (2022). Current Advances in the Development of Drug and Vaccine for Tuberculosis Prevention and Treatment. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 1–11. https://ajindex.com/articles/508614

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Molicotti P, Bua A, Zanetti S. Cost-effectiveness in the diagnosis of tuberculosis: choices in developing countries. J Infect DevCtries 2014;8:24–38
  2. Peter SK, Mamodikoe M, Christine S, Richard H. Viewpoint: Challenges and Opportunities in Tuberculosis Research. J Infect Dis 2012; 205:347–52
  3. Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clinical microbiology reviews 2014;18:687–702
  4. Tiemersma EW, Werf VMJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011;4:6:e17601
  5. WHO. Global tuberculosis report 2015, 20th ed. 1–3. Available at: https://apps.who.int/iris/handle/10665/191102. Accessed Jan 15, 2021
  6. Orme IM. Tuberculosis vaccine types and timings. Clin Vaccine Immunol 2015;22:249–57
  7. Manjelievskaia J, Erck D, Piracha S, Schrager L. Drug-resistant TB: Deadly, costly and in need of a vaccine. Transactions of the Royal Society of Tropical Medicine and Hygiene 2016;110:186– 91
  8. Ahsan MJ. Recent advances in the development of vaccines for tuberculosis. Therapeutic Advances in Vaccines 2015;3:66– 75
  9. Gaur PK, Mishra S. New Drugs and Vaccines for Tuberculosis. Recent Patents on Anti- Infective Drug Discovery 2017;12:147–61
  10. Abubakar I, Lipman M, McHugh TD. Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. BMC Med 2016;14:47
  11. Benabdellah A, Benchouk S, Taleb-Bendiab R, Sour N, AllalTaouli K. Recent Research and Review Studies for “Tuberculosis”. University of Tlemcen, Algeria 2016;1–4
  12. Brien R. Paul N. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. American Journal of Respiratory and Critical Care Medicine 2001;163:1055–8
  13. Deribew A, Deribe K, Dejene T, Tessema GA, Melaku YA, Lakew Y, et al. Tuberculosis Burden in Ethiopia from 1990 to 2016: Evidence from the Global Burden of Diseases 2016 Study. Ethiopian journal of health sciences 2018;28:519–28
  14. Nascimento IP, Leite CC. Recombinant vaccines and the development of new vaccine strategies. Brazilian Journal of Medical and Biological Research 2012;45:1102–11
  15. Brennan MJ, Fruth U, Milstien J, Tiernan R, Nishioka S, Chocarro L. Developing Countries Vaccine Regulatory Network and the Ad Hoc Regulatory and TB Expert Panel. Development of new tuberculosis vaccines: a global perspective o